Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $115 from $98 and keeps a Buy rating on the shares. The company’s partner Takeda presented positive Phase 3 VERIFY data, which highlighted the durability of rusfertide, the analyst tells investors in a research note. Citi now sees peak rusfertide worldwide sales in 2032 of $3B.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide
- Protagonist Therapeutics price target raised to $65 from $47 at Goldman Sachs
- Protagonist Therapeutics price target raised to $98 from $96 at Citi
- Protagonist Therapeutics price target raised to $81 from $68 at JPMorgan
- Protagonist Therapeutics price target raised to $88 from $72 at Barclays